• Lunit entered a strategic collaboration with Discovery Life Sciences to expand use of its SCOPE AI pathology platform in biopharma research.
• Deal integrates SCOPE into Discovery’s biomarker and tissue-analysis workflows, targeting standardized quantitative tissue readouts for drug development programs.
• Discovery’s biospecimen network and in-house labs support broader global access to Lunit’s AI analysis across translational studies and clinical research.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunit Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN69644) on October 12, 2026, and is solely responsible for the information contained therein.